WO2020235830A1 - 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소 - Google Patents

부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소 Download PDF

Info

Publication number
WO2020235830A1
WO2020235830A1 PCT/KR2020/005701 KR2020005701W WO2020235830A1 WO 2020235830 A1 WO2020235830 A1 WO 2020235830A1 KR 2020005701 W KR2020005701 W KR 2020005701W WO 2020235830 A1 WO2020235830 A1 WO 2020235830A1
Authority
WO
WIPO (PCT)
Prior art keywords
phosphate
enzyme
amino acid
motif
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2020/005701
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
윤상영
손병삼
조현국
박현준
김승환
양성재
박일향
김성보
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ CheilJedang Corp
Original Assignee
CJ CheilJedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ CheilJedang Corp filed Critical CJ CheilJedang Corp
Priority to CN202080028788.0A priority Critical patent/CN114008198B/zh
Priority to AU2020279663A priority patent/AU2020279663B2/en
Priority to JP2021549965A priority patent/JP7410162B2/ja
Priority to US17/612,970 priority patent/US12371686B2/en
Priority to EP20809298.1A priority patent/EP3916089A4/en
Publication of WO2020235830A1 publication Critical patent/WO2020235830A1/ko
Anticipated expiration legal-status Critical
Priority to JP2023128141A priority patent/JP7566993B2/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/03—Racemaces and epimerases (5.1) acting on carbohydrates and derivatives (5.1.3)
    • C12Y501/03001—Ribulose-phosphate 3-epimerase (5.1.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/02—Monosaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/24—Preparation of compounds containing saccharide radicals produced by the action of an isomerase, e.g. fructose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • the present application is a ribulose-phosphate 3-epimerization enzyme, in particular, a ribulose-phosphate 3-epimerization enzyme having low psychotic 3-epimerization activity, a composition for producing a lycose-6-phosphate or a lycose comprising the same, And it relates to a method for producing a Psychos-6-phosphate or Psicose using this.
  • ⁇ is an epimer of carbon 3 of fructose and is a monosaccharide known as rare sugar that exists in very small amounts in nature. Although it has about 70% sweetness of sugar, it is close to zero calories, and it is receiving a lot of interest as a new food raw material that can be used in functional foods with functions such as suppression of blood sugar increase and fat synthesis.
  • D-psicose 3-epimerase (EC 5.1.3.30) is capable of producing allulose by 3-epimerization (3-epimerization, 3 carbon epimerization) of fructose (D-fructose).
  • lycose-6-phosphate 3-epimerization enzymes have lycose 3-epimerization activity, they cannot be called specific enzymes for lycose-6-phosphate 3-epimerization and actually produce lycose. It is also not suitable for (WO2018/129275, WO2018/112139).
  • the applicant of the present invention confirmed that specific motifs are specifically important for the Psychos-6-phosphate 3-epimerization through investigation of the specific motif sequence that can affect the Pycos 3-epimerization activity.
  • One object of the present application is to provide a ribulose-phosphate 3-epimerase.
  • Another object of the present application is to provide a nucleic acid encoding a ribulose-phosphate 3-epimerase.
  • Another object of the present application is to provide a transformant comprising a nucleic acid encoding a ribulose-phosphate 3-epimerase.
  • Another object of the present application is to provide a composition for production of cycos-6-phosphate comprising a ribulose-phosphate 3-epimerase, a microorganism expressing the same, or a culture of the microorganism.
  • Another object of the present application is a step of contacting fructose-6-phosphate with a ribulose-phosphate 3-epimerase, a microorganism expressing the same, or a culture of the microorganism. It is to provide a method for producing Psychos-6-phosphate.
  • Another object of the present application is to provide a composition for production of psychoses comprising a ribulose-phosphate 3-epimerase, a microorganism expressing the same, or a culture of the microorganism.
  • Another object of the present application is a step of contacting fructose-6-phosphate with a ribulose-phosphate 3-epimerase, a microorganism expressing the same, or a culture of the microorganism. It is to provide a method of manufacturing a psychological course.
  • the ribulose-phosphoric acid 3-epimerization enzyme of the present application not only has low-cycose 3-epimerization activity by not including a specific motif, but also has heat resistance, so it has an advantage in industrial use, such as producing psychose. .
  • FIG. 1 is a diagram showing the protein structure predicted from the amino acid sequence of ribulose-phosphate 3-epimerase (SEQ ID NO: 9: KPL22606).
  • FIG. 2 is a diagram showing an HPLC chromatogram of a known Psychos-6-phosphate 3-epimerase (ADL69228; solid line) and an enzyme of the present application (SEQ ID NO: 20; dotted line).
  • One aspect of the present application for achieving the above object is to provide a ribulose-phosphate 3-epimerase.
  • the ribulose-phosphate 3-epimerase of the present application includes motif I consisting of the amino acid sequence of SEQ ID NO: 1 and motif III consisting of the amino acid sequence of SEQ ID NO: 3, and is highly active and heat-resistant ribulose-phosphate 3 -It may be an epimerization enzyme, and more specifically, may not include motif II consisting of the amino acid sequence of SEQ ID NO: 2, but is not limited thereto.
  • ribulose-phosphate 3-epimerase refers to an enzyme whose ribulose-phosphate 3-epimerization enzyme activity is known or has ribulose-phosphate 3-epimerization enzyme activity, and in particular, fructose- It means that it can act as a 6-phosphate 3-epimerase or a psicose-6-phosphate 3-epimerase.
  • fructose-phosphate 3-epimerase has the activity of fructose-6-phosphate 3-epimerase or psicose-6-phosphate 3-epimerase, some sequences These deletions, modifications, substitutions, conservative substitutions, or added amino acid sequences may also be included.
  • the enzyme of the present application is an enzyme having a reversible conversion activity having an activity of reversibly converting thycose-6-phosphate to fructose-6-phosphate or fructose-6-phosphate to thycose-6-phosphate
  • ribulose-phosphate 3-epimerase may be used interchangeably with “psicose-6-phosphate 3-epimerase” or "enzyme”.
  • the enzyme of the present application is glucose-1-phosphate (D-glucose-1-phosphate), glucose-6-phosphate (D-glucose-6-phosphate) or fructose-6-phosphate (D-fructose-6-phosphate) When mixed, it may be an enzyme that converts to psychos-6-phosphate.
  • the enzyme of the present application has a conversion rate of 1% or more to Psychos-6-phosphate when the same amount of Psychos-6-phosphate, glucose-1-phosphate, glucose-6-phosphate, and fructose-6-phosphate are mixed. , 10% or more, or 30% or more. Due to the selective activity of the enzymes of the present application, a high rate of conversion of psychoses can be exhibited in one-pot enzymatic conversion using a plurality of enzymes and substrates simultaneously.
  • motif refers to a site (region) having a specific sequence in an enzyme sequence, and may mean a sequence having a specific function or activity of a protein, and may be a sequence conserved between microorganism species. It is not limited.
  • the ribulose-phosphoric acid 3-epimerization enzyme of the present application may include motif I consisting of the amino acid sequence of SEQ ID NO: 1 and motif III consisting of the amino acid sequence of SEQ ID NO: 3.
  • it may be characterized in that it does not include motif II consisting of the amino acid sequence of SEQ ID NO: 2, and by not including the motif II, the enzyme is characterized by having a low lycose-3-epimerization activity.
  • the enzyme has 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, or activity of converting thycose to fructose compared to enzymes that do not contain motifs I and III. It may be absent, but is not limited thereto.
  • the enzyme of the present application may further include a motif consisting of the amino acid sequence of SEQ ID NO: 4 or 5.
  • the enzyme of the present application may contain a specific motif, or may necessarily contain a specific motif, and is characterized in that it does not contain a specific motif.
  • motifs I and III of the present application are included in a site (binding site, binding site) where an enzyme reacts by partially or entirely binding with a substrate and/or metal ion (eg, Mg, Mn, Zn, etc.) It may be to lower side-reactivity while maintaining the activity of the enzyme itself. More specifically, the motifs I and III may be included in the TIM-barrel fold in the bonding site.
  • Enzymes "comprising" a specific motif may or may not additionally include other motifs, domains, amino acid sequences, fragments, etc.
  • enzymes "essentially" containing a specific motif may or may not include the motif. Including, it is possible to obtain a desired property or characteristic, and may or may not further include other motifs, domains, amino acid sequences, fragments, etc. in addition to the corresponding motif, but is not limited thereto.
  • An enzyme that "does not contain" a specific motif does not include a sequence corresponding to the motif in the enzyme, and other amino acid sequences at the position of the motif may be inserted, substituted, deleted, or a combination thereof, but is not limited thereto. .
  • motifs included or not included in the enzyme of the present application may or may not be included independently of each other, and are not limitedly arranged in a specific order or position.
  • the enzyme of the present application comprises only motif I of SEQ ID NO: 1; Comprises motif I of SEQ ID NO: 1, and motif III of SEQ ID NO: 3, and does not include motif II of SEQ ID NO: 2; It may be an enzyme including motif I of SEQ ID NO: 1, motif III of SEQ ID NO: 3, and motifs of SEQ ID NOs: 4 and 5, and does not include motif II of SEQ ID NO: 2, but is not limited thereto.
  • Motif I may be composed of the amino acid sequence of SEQ ID NO: 1, but includes insertion, substitution, deletion, etc. of meaningless amino acid residues that do not affect the activity of the amino acid sequence of SEQ ID NO: 1 It is obvious that the sequence corresponds to the motif I of the present application.
  • the motif I may be included in a binding site that reacts with a substrate of a ribulose-phosphate 3-epimerase and a metal ion, but is not limited thereto.
  • the motif may be located at amino acids 173 to 184 from the first amino acid at the N-terminal of the ribulose-phosphate 3-epimerase, but is not limited thereto. That is, valine (V), which is the first amino acid residue of motif I, may be located between 173 and 182 from the first amino acid of the N-terminus of the ribulose-phosphate 3-epimerase, and is the last residue of motif I.
  • Glycine (G) may be located between 175 and 184, but is not limited thereto.
  • the motif I may be that the first amino acid residue starts at the C-terminus from the domain to which the first beta sheet structure-coil structure-alpha helix structure-second beta sheet structure is linked to the second beta sheet, and the domain is bound It may be included in the region or may have a structure in which some regions overlap (FIG. 1).
  • Motif II may be composed of the amino acid sequence of SEQ ID NO: 2, but includes insertions, substitutions, deletions, etc. of meaningless amino acid residues that do not affect the activity of the amino acid sequence of SEQ ID NO: 2 It is obvious that the sequence corresponds to the motif II of the present application.
  • the motif II may be included in the N-terminal region of the ribulose-phosphate 3-epimerase, but is not limited thereto. Specifically, the motif may be located at amino acids 136 to 150 from the first amino acid of the N-terminal of the ribulose-phosphate 3-epimerase, but is not limited thereto. That is, methionine (M), which is the first amino acid residue of motif II, may be located between 136 and 145 times from the first amino acid of the N-terminal of the ribulose-phosphate 3-epimerase, and is the last residue of motif II. Glycine (G) may be located between 141 and 150, but is not limited thereto.
  • the motif II may be that the first amino acid residue starts at the C-terminus of the first beta sheet in the domain to which the first beta sheet structure-coil structure-alpha helix structure-second beta sheet structure is connected, and the domain is a binding site It may be included in or may have a structure in which some regions overlap, and the domain may be the same as the domain including the motif I (FIG. 1).
  • any amino acid may be included in X without limitation, and specifically, threonine (T) and valine (V) may be used, but the present invention is not limited thereto. More specifically, the motif II may include the sequence of M-(T/A/M/L)-(V/N/I)-D-P-G, but is not limited thereto.
  • Motif III may be composed of the amino acid sequence of SEQ ID NO: 3, but includes insertions, substitutions, deletions, etc. of meaningless amino acid residues that do not affect the activity of the amino acid sequence of SEQ ID NO: 3 It is obvious that the sequence corresponds to the motif III of the present application.
  • Motif III (SEQ ID NO: 3): M-X-X-X'-P-G (X is any amino acid residue)
  • the motif III may be included in the N-terminal region of the ribulose-phosphate 3-epimerase, but is not limited thereto. Specifically, the motif may be located at amino acids 136 to 150 from the first amino acid of the N-terminal of the ribulose-phosphate 3-epimerase, but is not limited thereto. That is, methionine (M), which is the first amino acid residue of motif III, may be located between 136 and 145 from the first amino acid of the N-terminal of the ribulose-phosphate 3-epimerase, and is the last residue of motif III. Glycine (G) may be located between 141 and 150, but is not limited thereto.
  • the motif III may be that the first amino acid residue starts at the C-terminus of the first beta sheet in the domain to which the first beta sheet structure-coil structure-alpha helix structure-second beta sheet structure is connected, and the domain is a binding site It may be included in or may have a structure in which some regions overlap, and the domain may be the same as the domain including the motif I (FIG. 1).
  • motifs II and III may be motifs included in the same position when the enzymes of the present application are aligned, but are not limited thereto.
  • the X may contain any amino acid without limitation, specifically threonine (T), alanine (A), methionine (M), leucine (L), valine (V), asparagine (N), isoleucine ( I) may be, but is not limited thereto.
  • T threonine
  • A alanine
  • M methionine
  • L leucine
  • V valine
  • N asparagine
  • I isoleucine
  • X′ may include any amino acid other than aspartic acid (D) without limitation, and specifically, an amino acid residue having no charge or an amino acid having a positive charge may be included.
  • the uncharged amino acid includes both polar and non-polar amino acids, and may be any one of serine, threonine, cysteine, asparagine, glutamine, glycine, alanine, proline, valine, leucine, isoleucine, and methionine.
  • the positively charged amino acid may be any one of lysine, arginine, and histidine.
  • asparagine (N) and lysine (K) may be included.
  • the motif III may include the sequence of M-(T/A/M/L)-(V/N/I)-N-P-G, but is not limited thereto.
  • the enzyme of the present application may additionally include a motif consisting of the amino acid sequence of SEQ ID NO: 4, but including insertion, substitution, deletion, etc. of meaningless amino acid residues that do not affect the activity of the amino acid sequence of SEQ ID NO: 4 It is obvious that the sequence is included in the enzyme of the present application.
  • SEQ ID NO: 4 S-X-M/I-C (X is any amino acid residue)
  • the motif having the amino acid sequence of SEQ ID NO: 4 may be included in the N-terminal region of the ribulose-phosphate 3-epimerase, but is not limited thereto. Specifically, the motif may be located at amino acids 5 to 20, more specifically, 7 to 19 from the first amino acid of the N-terminal of the ribulose-phosphate 3-epimerase, but is not limited thereto. .
  • serine (S), which is the first amino acid residue of the motif having the amino acid sequence of SEQ ID NO: 4, may be located between 7 and 16 from the first amino acid of the N-terminus of the ribulose-phosphate 3-epimerase, , Cysteine (C), which is the last residue of the motif having the amino acid sequence of SEQ ID NO: 4, may be located between 10 and 19, but is not limited thereto.
  • the motif of SEQ ID NO: 4 may be formed after the beta sheet structure, and specifically, a part of the motif sequence of SEQ ID NO: 4 may be included in the alpha helix structure formed after the beta sheet structure.
  • the X may include any amino acid without limitation, and specifically, may be methionine, isoleucine, leucine, or valine, but is not limited thereto. More specifically, the motif consisting of the amino acid sequence of SEQ ID NO: 4 may include a sequence of SIMC (SEQ ID NO: 27), SMMC (SEQ ID NO: 28), SLMC (SEQ ID NO: 29) or SVMC (SEQ ID NO: 30), It is not limited thereto.
  • SIMC SEQ ID NO: 27
  • SMMC SEQ ID NO: 28
  • SLMC SEQ ID NO: 29
  • SVMC SEQ ID NO: 30
  • the enzyme of the present application may additionally include a motif composed of the amino acid sequence of SEQ ID NO: 5, but including insertion, substitution, deletion, etc. of meaningless amino acid residues that do not affect the activity of the amino acid sequence of SEQ ID NO: 5 It is obvious that the sequence is included in the enzyme of the present application.
  • SEQ ID NO: 5 G-X-X-X-X-F/L (X is any amino acid residue)
  • the motif consisting of the amino acid sequence of SEQ ID NO: 5 may be included in the C-terminal region of the ribulose-phosphate 3-epimerase, but is not limited thereto.
  • the ribulose-phosphoric acid 3-epimerization enzyme may be positioned at amino acids 190 to 210 times, more specifically 196 to 210 times from the N-terminal amino acid of the enzyme, but is not limited thereto.
  • glycine (G) which is the first amino acid residue of the motif consisting of the amino acid sequence of SEQ ID NO: 5 may be located between 196 and 205 from the first amino acid of the N-terminus of the ribulose-phosphate 3-epimerase, , Phenylalanine (F), which is the last residue of the motif consisting of the amino acid sequence of SEQ ID NO: 5, may be located between 201 and 210, but is not limited thereto.
  • the motif of SEQ ID NO: 5 may be formed after the beta sheet structure, and specifically, a part of the motif sequence of SEQ ID NO: 5 may be included in the alpha helix structure formed after the beta sheet structure.
  • each X of the motif consisting of the amino acid sequence of SEQ ID NO: 5 may be independently of each other, threonine, serine, glycine, leucine, cysteine, isoleucine, asparagine, lysine, alanine, valine, or glutamine, It is not limited thereto.
  • the motif consisting of the amino acid sequence of SEQ ID NO: 5 is GNSGLF (SEQ ID NO: 31), GSSGLFGSSSLF (SEQ ID NO: 32), GSTSLF (SEQ ID NO: 33), GTAGLF (SEQ ID NO: 34), GTKGLF (SEQ ID NO: 35), Amino acids of GTQSLF (SEQ ID NO: 36), GTSCLF (SEQ ID NO: 37), GTSGLF (SEQ ID NO: 38), GTSSIF (SEQ ID NO: 39), GTSGIF (SEQ ID NO: 40), GTSSLF (SEQ ID NO: 41) or GTSSVF (SEQ ID NO: 42) It may include a sequence, but is not limited thereto.
  • the enzyme of the present application is characterized by having a high activity of converting fructose-6-phosphate to lycose-6-phosphate by including the motif of SEQ ID NO: 4 and/or 5.
  • Each amino acid residue included in the motif of the present application may be independently combined to form a motif.
  • the ribulose-phosphate 3-epimerase of the present application may exhibit very low thycose 3-epimerization activity by not including a specific motif, that is, II, which is from fructose-6-phosphate.
  • a specific motif that is, II, which is from fructose-6-phosphate.
  • the alpha helix ( ⁇ -helix) structure, beta sheet ( ⁇ -sheet) structure, and coil structure of the present application are described in KwangsooKim et. al (Crystal Structure of d-Psicose 3-epimerase from Agrobacterium tumefaciens and its Complex with True Substrate d-FructoseVolume 361, Issue 5, 1 September 2006, Pages 920-931), etc.
  • the alpha helix may be a right handed alpha helix.
  • the structure can be directly performed by commonly known methods such as NMR and X-ray crystallography, or can be obtained by predicting using Rosetta or a web server (I-TASSER, ROBETTA, etc.) based on the amino acid sequence.
  • the domain in which the structures are aggregated may be displayed in the same form as Structure 1-Structure 2.
  • ribul Ross-phosphate 3-epimerase is keusso eggplant grandma (Chthonomonas), geo Bacillus (Geobacillus), e HeLa (Mahella), Thermo unloading area tumefaciens (Thermoanaerobacterium), te the blood Nero bakteo (Tepidanaerobacter) , Arden urticae'll ah (Ardenticatenia), permeation kyucheu (Firmicutes), Arianna Bacillus of any one of the origin is selected from (Aeribacillus), the group consisting of in fish Titanium (Epulopiscium), and the thermopile away flaviviruses micro (Thermoflavimicrobium) to yipul It may be, and more specifically, Chthonomonas calidirosea T49, Geobacillus sp .
  • Geobacillus thermocatenulatus Geobacillus thermocatenulatus
  • Macella australiensis Mahella australiensis
  • Thermoanaerobacterium sp . PSU-2 Thermoanaerobacterium thermosaccharolyticum, Tepidanaerobacterium syntropycus syntrophicus ), Ardenticatenia bacterium , Firmicutes bacterium HGW-Firmicutes-5 ( Firmicutes bacterium HGW-Firmicutes-5), Aeribacillus pallidus , Aeribacillus pallidus , genus Ipulopisium SCG-B05WGA -EpuloA1 ( Epulopiscium sp.SCG -B05WGA-EpuloA1), And Thermoflavimicrobium dichotomicum may be derived from any one selected from the group consisting of, but is not limited thereto.
  • the ribulose-phosphate 3-epimerization enzyme of the present application may include any one sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 15 to 26, or the amino acid sequences of SEQ ID NOs: 15 to 26. It may be composed of any one sequence selected from the group consisting of, but is not limited thereto. More specifically, the enzyme may be composed of the amino acid sequence of SEQ ID NO: 19, 20, or 22, but is not limited thereto.
  • the presence or absence of a specific motif has an important influence on the enzyme activity, and thus the enzyme sequence excluding the motif region may have low sequence identity.
  • the amino acid may include an amino acid sequence of any one of SEQ ID NOs: 15 to 26 or an amino acid sequence having 70% or more homology or identity thereto, but is not limited thereto.
  • the amino acid is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more homology with the sequence of SEQ ID NO: 15 to 26 and the sequence Or it may include amino acids having identity.
  • proteins having an amino acid sequence in which some sequences are deleted, modified, substituted or added are also included within the scope of the present application, as long as they have homology or identity and an amino acid sequence exhibiting efficacy corresponding to the protein.
  • the term'homology' or'identity' means the degree to which two given amino acid sequences or base sequences are related to each other, and may be expressed as a percentage.
  • sequence homology or identity of a conserved polynucleotide or polypeptide is determined by standard alignment algorithms, and a default gap penalty established by the program used can be used together.
  • sequence homologous or identical sequences are generally at least about 50%, 60%, 70%, 80% of the sequence full or full-length in medium or high stringent conditions. Or it can hybridize to 90% or more. Hybridization is also contemplated for polynucleotides containing degenerate codons instead of codons in the polynucleotide.
  • the homology, similarity or identity of a polynucleotide or polypeptide can be found in, eg, Smith and Waterman, Adv. Appl. As known in Math (1981) 2:482, for example, Needleman et al. (1970), J Mol Biol. 48: 443 can be determined by comparing sequence information using a GAP computer program.
  • the GAP program defines the total number of symbols in the shorter of two sequences, divided by the number of similarly aligned symbols (ie, nucleotides or amino acids).
  • the default parameters for the GAP program are (1) a monolithic comparison matrix (contains values of 1 for identity and 0 for non-identity) and Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. As disclosed by 353-358 (1979), Gribskov et al (1986) Nucl. Acids Res. 14: weighted comparison matrix of 6745 (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); And (3) no penalty for end gaps.
  • the term “homology” or “identity” refers to relevance between sequences.
  • the ribulose-phosphate 3-epimerization enzyme of the present application may be heat resistant, but is not limited thereto.
  • heat resistance refers to a property capable of exhibiting the original activity without losing the activity of the enzyme even in a high temperature environment, and the heat resistance of the enzyme has various advantages in the process of producing a target product.
  • the ribulose-phosphate 3-epimerization enzyme of the present application may have a thycose-6-phosphate 3-epimerization activity at 40°C or higher, more specifically 50°C or higher, and more specifically 60°C or higher. , But is not limited thereto.
  • the enzyme of the present application may be one having a thycose-6-phosphate 3-epimerization activity for 1 minute to 24 hours under conditions of pH 5.0 to 10.0 and 50°C to 90°C, but is not limited thereto.
  • the ribulose-phosphate 3-epimerization enzyme of the present application transforms the enzyme itself or the DNA expressing the same into a strain, and cultivates it to obtain a culture, crushing the culture, and purifying it through a column.
  • the strains for transformation include Escherichia coli , Corynebacterum glutamicum , Aspergillus oryzae , Saccharomyces cerevisiae , and Yarrowia lee.
  • Polytica Yarrowia lipolytica
  • Pichia pastoris Pichia pastoris
  • Bacillus subtilis Bacillus subtilis
  • GRAS Generally Recognized as Safe
  • the method for purifying the ribulose-phosphate 3-epimerization enzyme of the present application is not particularly limited, and a method commonly used in the technical field of the present application may be used. Non-limiting examples include chromatography, heat treatment, adsorption, filtration, and ion purification. Only one purification method may be performed, or two or more methods may be performed together.
  • Another aspect of the present application is to provide a nucleic acid encoding the ribulose-phosphate 3-epimerase enzyme, or a vector including the nucleic acid.
  • nucleic acid has the meaning of comprehensively including a DNA or RNA molecule, and a nucleotide, which is a basic structural unit in a nucleic acid, may include not only natural nucleotides but also analogs with modified sugar or base moieties.
  • the nucleic acid of the present application may be a DNA or RNA sequence in which nucleotides as a unit are covalently linked, and specifically, all possible when converting the amino acid sequence of SEQ ID NOs: 15 to 26 into DNA (modifying amino acids into 61 codons) It may be any one of the number of nucleotide sequences, and more specifically, each nucleotide that can be translated into any one of the amino acid sequences of SEQ ID NOs: 15 to 26 of the present application and 90% or more, 95% or more, 97 % Or more, 99% or more, or 100% of homology, similarity or identity, and may contain a nucleic acid capable of being translated to exhibit a desired enzymatic activity.
  • a protein having the same activity by codon degeneracy, having the same amino acid sequence after translation specifically, a protein consisting of any one of SEQ ID NOs: 15 to 26, or homology, similarity, or identity thereto
  • a polynucleotide capable of being translated into a protein branch can also be included in the scope of the present application. More specifically, the sequence of the nucleic acid of the present application is not separately indicated, and may be composed of all DNA codon branches that can be translated into SEQ ID NO: 15 to 26 amino acid sequence, but is not limited thereto.
  • probes that can be prepared from a known gene sequence, for example, a complementary sequence for all or part of the nucleotide sequence, and a sequence encoding the enzyme of the present application by hydride under stringent conditions may be included without limitation. .
  • the "stringent condition” means a condition that enables specific hybridization between polynucleotides. These conditions are specifically described in the literature (eg, J. Sambrook et al., homolog). For example, between genes with high homology or identity, 80% or more, 85% or more, specifically 90% or more, more specifically 95% or more, more specifically 97% or more, Particularly, under the condition that genes with 99% or more homology or identity are hybridized, and genes with lower homology or identity are not hybridized, or at 60°C, which is a washing condition for common southern hybridization , 1 X SSC, 0.1% SDS, specifically 60° C., 0.1 X SSC, 0.1% SDS, more specifically 68° C., 0.1 X SSC, at a salt concentration and temperature corresponding to 0.1% SDS, once, specifically Conditions for washing 2 times to 3 times can be listed as examples.
  • Hybridization requires that two nucleic acids have a complementary sequence, although a mismatch between bases is possible depending on the stringency of the hybridization.
  • complementary is used to describe the relationship between nucleotide bases capable of hybridizing to each other. For example, with respect to DNA, adenosine is complementary to thymine and cytosine is complementary to guanine.
  • the present application may also include substantially similar nucleic acid sequences as well as isolated nucleic acid fragments that are complementary to the entire sequence.
  • polynucleotides having homology or identity can be detected using hybridization conditions including a hybridization step at a Tm value of 55° C. and using the above-described conditions.
  • the Tm value may be 60°C, 63°C, or 65°C, but is not limited thereto and may be appropriately adjusted by a person skilled in the art according to the purpose.
  • the appropriate stringency to hybridize a polynucleotide depends on the length and degree of complementarity of the polynucleotide, and the parameters are well known in the art.
  • vector refers to a DNA preparation containing a nucleotide sequence of a nucleic acid encoding an enzyme of the present application operably linked to a suitable regulatory sequence so that the desired variant protein can be expressed in a suitable host.
  • the regulatory sequence may include a promoter capable of initiating transcription, any operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence controlling termination of transcription and translation.
  • Vectors can be transformed into a suitable host cell and then replicated or function independently of the host genome, and can be integrated into the genome itself.
  • the vector used in the present application is not particularly limited as long as it can be replicated in the host cell, and any vector known in the art may be used.
  • Examples of commonly used vectors include natural or recombinant plasmids, cosmids, viruses and bacteriophages.
  • pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, Charon21A, etc. can be used as a phage vector or a cosmid vector, and as a plasmid vector, pBR system, pUC system, pBluescriptII system , pGEM system, pTZ system, pCL system, pET system, etc. can be used.
  • pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors, and the like can be used.
  • Another aspect of the present application provides a transformant comprising a nucleic acid encoding an enzyme of the present application or a vector comprising a nucleic acid encoding the enzyme of the present application.
  • a transformant comprising a nucleic acid encoding an enzyme or "a transformant comprising a vector comprising a nucleic acid encoding an enzyme” refers to the ribulose-phosphate 3-epimerization enzyme of the present application It may mean a microorganism recombined to be expressed. For example, it is transformed with a vector containing a nucleic acid encoding a ribulose-phosphate 3-epimerase, or a vector containing a nucleic acid encoding a ribulose-phosphate 3-epimerase, and the ribulose-phosphate 3-epi It refers to a host cell or microorganism capable of expressing a merase enzyme.
  • the ribulose-phosphate 3-epimerization enzyme expressed by the transformant may be composed of any one amino acid sequence of SEQ ID NOs: 15 to 26, but is not limited thereto.
  • the term "transformation” refers to the introduction of a vector containing a nucleic acid encoding the ribulose-phosphate 3-epimerase of the present application into a host cell so that the protein encoded by the nucleic acid can be expressed in the host cell. Means to do.
  • the transformed nucleic acid can include all of them, whether inserted into the chromosome of the host cell or located outside the chromosome, as long as it can be expressed in the host cell.
  • the nucleic acid includes DNA and RNA encoding the nucleic acid encoding the ribulose-phosphate 3-epimerase of the present application.
  • the nucleic acid may be introduced into a host cell and expressed in any form as long as it can be expressed.
  • the nucleic acid may be introduced into a host cell in the form of an expression cassette, which is a gene construct containing all elements necessary for self-expression.
  • the expression cassette may generally include a promoter operably linked to the nucleic acid, a transcription termination signal, a ribosome binding site, and a translation termination signal.
  • the expression cassette may be in the form of an expression vector capable of self-replicating.
  • the nucleic acid may be introduced into a host cell in its own form and operably linked to a sequence required for expression in the host cell, but is not limited thereto.
  • operably linked refers to a promoter sequence for initiating and mediating the transcription of a nucleic acid encoding the dephosphorylation enzyme of Pycos-6-phosphate of the present application and the gene sequence is functionally linked. Means that.
  • Insertion of the nucleic acid or vector into the chromosome may be performed by any method known in the art, for example, homologous recombination, but is not limited thereto.
  • a selection marker for confirming whether the chromosome is inserted may be additionally included.
  • Selectable markers are used to select cells transformed with a vector, that is, to confirm the insertion of a nucleic acid molecule of interest, and selectable phenotypes such as drug resistance, nutrient demand, resistance to cytotoxic agents, or expression of surface variant proteins. Markers that give s can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, and thus transformed cells can be selected.
  • the method of transforming the vector of the present application includes any method of introducing a nucleic acid into a cell, and may be performed by selecting an appropriate standard technique as known in the art depending on the host cell. For example, electroporation, calcium phosphate (CaPO 4 ) precipitation, calcium chloride (CaCl 2 ) precipitation, retroviral infection, microinjection, polyethylene glycol (PEG) method, DEAE-dex Tran method, cationic liposome method, and lithium acetate-DMSO method, and the like, but are not limited thereto.
  • electroporation calcium phosphate (CaPO 4 ) precipitation, calcium chloride (CaCl 2 ) precipitation, retroviral infection, microinjection, polyethylene glycol (PEG) method, DEAE-dex Tran method, cationic liposome method, and lithium acetate-DMSO method, and the like, but are not limited thereto.
  • the host cell it is good to use a host with high DNA introduction efficiency and high expression efficiency of the introduced DNA, for example, microorganisms of the genus Coryne, microorganisms of the genus Escherichia, microorganisms of the genus Serratia, microorganisms of the genus Bacillus, It may be a microorganism of the genus Romisis cerevise or a microorganism of the genus Pichia, specifically E. coli , but is not limited thereto, and is applicable to all GRAS strains.
  • E.coil BL21(DE3)/pET-CJ-ef7 E.coil BL21(DE3)/pET-CJ-ef12
  • E.coil BL21(DE3)/ pET- CJ-ef15 May be, but is not limited thereto.
  • Another aspect of the present application provides a ribulose-phosphate 3-epimerase, a microorganism expressing the same, or a composition for producing thycose-6-phosphate comprising a culture of the microorganism.
  • the composition for the production of Pycos-6-phosphate of the present application is a ribulose-phosphate 3-epimerization enzyme that exhibits the activity of converting fructose-6-phosphate to Pycose-6-phosphate, a microorganism expressing the same, or of the microorganism Since it includes a culture, when the composition is contacted (reacted) with fructose-6-phosphate, it is possible to produce thycose-6-phosphate from the fructose-6-phosphate.
  • composition may further include fructose-6-phosphate as a substrate, but is not limited thereto.
  • composition for producing Psychos-6-phosphate of the present application may further include any suitable excipients commonly used in the composition for producing Pycos-6-phosphate.
  • excipients may include, for example, a preservative, a wetting agent, a dispersing agent, a suspending agent, a buffering agent, a stabilizer, and an isotonic agent, but are not limited thereto.
  • the composition for producing Psychos-6-phosphate of the present application may further include a metal ion or a metal salt.
  • the metal ion may be a divalent cation, and specifically, may be one or more metal ions selected from the group consisting of Ni, Mg, Ni, Co, Mn, Fe, and Zn.
  • the composition for production of Psychos-6-phosphate of the present application may additionally include a metal salt, and more specifically, the metal salt is NiSO 4 , MgSO 4 , MgCl 2 , NiCl 2 , CoSO 4 , It may be one or more selected from the group consisting of CoCl 2 , MnCl 2 , MnSO 4 , FeSO 4 and ZnSO 4 .
  • Another aspect of the present application comprises the step of contacting fructose-6-phosphate with a ribulose-phosphate 3-epimerase, a microorganism expressing the same, or a culture of the microorganism. It provides a method for producing Psychos-6-phosphate.
  • the ribulose-phosphate 3-epimerization enzyme of the present application exhibits an activity of converting fructose-6-phosphate into thycose-6-phosphate, the ribulose-phosphate 3-epimerization enzyme, a microorganism expressing it, or When the culture of the microorganism is brought into contact with fructose-6-phosphate, it is possible to produce thycose-6-phosphate from the fructose-6-phosphate.
  • Conditions for reacting by contacting the fructose-6-phosphoric acid and thycose-6-phosphate can be appropriately selected and carried out by a person skilled in the art in consideration of substrates and enzymes.
  • the step of producing thycose-6-phosphate by contacting the fructose-6-phosphate and ribulose-phosphate 3-epimerase enzyme is pH 5.0 to 9.0, 40 to 80°C temperature, and/or 2 hours To 24 hours, more specifically pH 6.0 to pH 8.0, 40°C to 60°C temperature, and/or may be performed for 20 hours to 24 hours, more specifically pH 7.0, 50 It may be performed at °C temperature, 24 hours, but is not limited thereto.
  • the method for preparing Psychos-6-phosphate of the present application may additionally include obtaining and/or purifying the prepared Psychos-6-phosphate, but is not limited thereto.
  • the step of obtaining and/or purifying the Psychos-6-phosphate may be performed by a method known in the art, and is not limited to a specific method.
  • compositions for producing a psychosis comprising a ribulose-phosphate 3-epimerase, a microorganism expressing the same, or a culture of the microorganism.
  • the composition may further include fructose-6-phosphate as a substrate, but is not limited thereto.
  • the composition for the production of psychosis of the present application for example, an enzyme required to produce the psychosis, It may be to produce a lycose by additionally including a lycose-6-phosphate dephosphorylation enzyme that produces a lycose by dephosphorylating the phosphate of -6-phosphate.
  • the composition for the production of thycose of the present application is glucose-6-phosphate-isomerase, phosphoglucomutase, polyphosphate glucose phosphorylase, ⁇ -glucan phosphorylase, starch phosphorylase, maltodextrin phosphine
  • One or more enzymes selected from, a microorganism expressing the same, or a culture of the microorganism may additionally be included, and specifically, may further include a thycose-6-phosphate dephosphorylation enzyme, but is limited thereto. no.
  • composition for producing psychos of the present application is a composition for producing psychos of the present application.
  • a culture of microorganisms expressing the enzyme of item (a) or a microorganism expressing the enzyme of item (a) may additionally be included, but is not limited thereto.
  • the ribulose-phosphate 3-epimerization enzyme of the present application can be used to produce the lycose, the enzyme contained in the composition for producing the lycose and the substrate used in the production of the lycose are limited. It doesn't work.
  • starch / maltodextrin phosphorylase starch / maltodextrin phosphorylase, EC 2.4.1.1
  • ⁇ -glucan phosphorylase of the present application are glucose from starch or maltodextrin by phosphorylation transfer of phosphate to glucose. Any protein may be included as long as it has an activity of producing -1-phosphate.
  • the starch/maltodextrin phosphorylase starch/maltodextrin phosphorylase, EC 2.4.1.1
  • ⁇ -glucan phosphorylase phosphorylate phosphate to glucose to transfer glucose-1-phosphate from starch or maltodextrin. Any protein can be included as long as it has an activity to produce.
  • the sucrose phosphorylase (EC 2.4.1.7) may include any protein as long as it has the activity of producing glucose-1-phosphate from sucrose by phosphorylating phosphate to glucose.
  • the starch glycosylation enzyme ⁇ -amylase ( ⁇ -amylase, EC 3.2.1.1), pullulanse (EC 3.2.1.41), isoamylase (EC 3.2.1.68), 4- ⁇ -glucanotrans Perase (4- ⁇ -glucanotransferase, EC 2.4.1.25) and glucoamylase (EC 3.2.1.3) are any protein that has the activity of converting starch or maltodextrin into debranched maltooligosaccharide or glucose. Can include.
  • the sucrase (EC 3.2.1.26) may include any protein as long as it has an activity of converting sucrose into glucose.
  • the phosphoglucomutase (EC 5.4.2.2) of the present application may include any protein as long as it has an activity of converting glucose-1-phosphate into glucose-6-phosphate.
  • Polyphosphate glucokinase (EC 2.7.1.63) may contain any protein as long as it has the activity of converting the phosphate of polyphosphate to glucose and converting it into glucose-6-phosphate.
  • the glucose-6-phosphate-isomerase of the present application may include any protein as long as it has an activity of converting glucose-6-phosphate into fructose-6-phosphate.
  • the Pycose-6-phosphate dephosphorylation enzyme of the present application may include any protein as long as it has an activity of converting Pycose-6-phosphate into Pycose. More specifically, the lycose-6-phosphate dephosphorylation enzyme may be a protein having an activity of irreversibly converting lycose-6-phosphate into lycose.
  • Enzymes included in the composition for producing a psychosis of the present application may exhibit a high rate of conversion of a psychotic in one-pot enzymatic conversion using a plurality of enzymes and substrates simultaneously.
  • composition for producing a Pycose of the present application may further include any suitable excipients commonly used in the composition for producing Pycose.
  • excipients may include, for example, a preservative, a wetting agent, a dispersing agent, a suspending agent, a buffering agent, a stabilizer, and an isotonic agent, but are not limited thereto.
  • the composition for producing psychos of the present application may further include a metal ion or a metal salt.
  • the metal ion may be a divalent cation, and specifically, may be one or more metal ions selected from the group consisting of Ni, Mg, Ni, Co, Mn, Fe, and Zn.
  • the composition for the production of psychoses of the present application may additionally include a metal salt, and more specifically, the metal salt is NiSO 4 , MgSO 4 , MgCl 2 , NiCl 2 , CoSO 4 , CoCl 2 , MnCl 2 , It may be one or more selected from the group consisting of MnSO 4 , FeSO 4 and ZnSO 4 .
  • Another aspect of the present application provides a method for producing a psychose comprising contacting fructose-6-phosphate with a ribulose-phosphate 3-epimerase, a microorganism expressing the same, or a culture of the microorganism. .
  • a microorganism expressing it, or a culture of the microorganism is brought into contact with Pycose-6-phosphate to convert Pycose-6-phosphate into Pycose.
  • the steps may be sequentially included, but are not limited thereto.
  • the method for preparing a lycose of the present application includes glucose-6-phosphate-isomerase in glucose-6-phosphate prior to the step of converting the fructose-6-phosphate to lycose-6-phosphate. , By contacting the culture of the microorganism expressing the glucose-6-phosphate-isomerase or the microorganism expressing the glucose-6-phosphate-isomerase, converting the glucose-6-phosphate into fructose-6-phosphate It may additionally include steps.
  • the method for preparing the thycose of the present application includes phosphoglucomutase in glucose-1-phosphate, and the phosphoglucomuta It may further include the step of converting the glucose-1-phosphate into glucose-6-phosphate by contacting the culture of the microorganism expressing the enzyme or the microorganism expressing the phosphoglucomutase.
  • the method for preparing the thycose of the present application includes a polyphosphate glucose phosphorylation enzyme in glucose, a microorganism expressing the polyphosphate glucose phosphorylation enzyme, or the poly It may further include the step of converting the glucose into glucose-6-phosphate by contacting a culture of a microorganism expressing a phosphate glucose phosphorylation enzyme, and a polyphosphate.
  • the method for preparing the thycose of the present application includes ⁇ -glucan phosphorylase, starch phosphorylase prior to the step of converting glucose-1-phosphate into glucose-6-phosphate, starch, maltodextrin, sucrose, or a combination thereof.
  • a step of converting the starch, maltodextrin, sucrose, or a combination thereof to glucose-1-phosphate by contacting the culture of the microorganism expressing the phosphorylase and phosphate may be additionally included.
  • the method for preparing the thycose of the present application is prior to the step of converting the starch, maltodextrin, sucrose or a combination thereof to glucose-1-phosphate, starch, maltodextrin, sucrose or a combination thereof, ⁇ -amylase, pullulanase, Isoamylase, glucoamylase, or sucrase; Microorganisms expressing the ⁇ -amylase, pullulanase, glucoamylase, sucrase, or isoamylase; Or by contacting a culture of a microorganism expressing the ⁇ -amylase, pullulanase, glucoamylase, sucrase or isoamylase, and converting the starch, maltodextrin, sucrose, or a combination thereof into glucose. can do.
  • the method of manufacturing the thycose of the present application may be to produce the optimal/maximum thycose in a complex combination with phosphate saccharide converting enzymes by decomposing a high concentration of starch, and a maximum of 8 types of enzymes are combined to secure the maximum productivity of the thycose. Can be used.
  • glucan phosphorylase (glycogen phosphorylase, EC 2.4.1.1), an enzyme that degrades starch and produces glucose-1-phosphate, is specifically glucose-1 in ⁇ -1,4 bound starch. -Produces phosphoric acid (glucose-1-phosphate).
  • phosphoglucomutase (EC 2.7.5.1) or phosphomannomutase (EC), which converts the thus produced glucose-1-phosphate into glucose-6-phosphate (glucose-6-phosphate). 5.4.2.8) is used in the intermediate complex enzyme reaction.
  • glucose-6-phosphate isomerase (EC 5.3.1.9), which converts glucose-6 phosphate to fructose-6-phosphate, is used.
  • pullulanase (EC 3.2.1.41) or isoamylase to break down branch bonds of ⁇ -1,4 and ⁇ -1,6 bonds of amylopectin (isoamylase EC 3.2.1.68)
  • Enzymes are used together, and in order to increase the utilization of starch by glucan phosphorylase, 4-alpha-glucanotransferase (EC 2.4.1.25) can be used.
  • 4-alpha-glucanotransferase (EC 2.4.1.25) can be used.
  • oligosaccharides in the form of ⁇ -1,4 bonds to maltose or other oligosaccharides, which are substrates with relatively low activity
  • the utilization rate of granular starch can be increased.
  • polyphosphate-glucose phosphotransferase (EC 2.7.1.63) can be used to produce additional psychoses through complex enzymatic reactions from degraded glucose after using starch.
  • the contact of the present application may be carried out at pH 5.0 to 9.0, specifically pH 6.0 to 8.0.
  • the contact of the present application may be carried out at a temperature of 40°C to 80°C, specifically 40°C to 60°C or 50°C to 60°C.
  • the contact of the present application may be carried out for 2 hours to 24 hours, specifically 6 to 24 hours.
  • the contact of the present application may be carried out for a pH of 5.0 to 9.0, a temperature of 40 to 80 °C, and/or 2 to 24 hours. Specifically, the contacting may be carried out for a pH of 6.0 to 8.0, a temperature of 40° C. to 60° C. or a temperature of 50° C. to 60° C., and/or 6 to 24 hours.
  • the method of manufacturing a Psychose of the present application may further include the step of purifying Psychose.
  • the tablet of the present application is not particularly limited, and a method commonly used in the technical field of the present application may be used. Non-limiting examples include chromatography, fractional crystallization, and ion purification. Only one purification method may be performed, or two or more methods may be performed together. For example, it is possible to purify a reaction product for generating a thycose through chromatography, and the separation of sugar by chromatography can be performed by using the difference in weak binding force between the sugar to be separated and the metal ion attached to the ionic resin. have.
  • the present application may further include performing decolorization, desalting, or both before or after the purification step of the present application.
  • performing decolorization, desalting, or both By performing the above decolorization and/or desalting, a more purified thycose reaction product without impurities can be obtained.
  • amino acids may be represented by the following abbreviations or amino acid names:
  • Example 1 Preparation of recombinant expression vector and transforming microorganism of each enzyme
  • the gene of the heat-resistant enzyme was selected in order to provide each enzyme necessary for the process for producing the psychosis of the present application, and an enzyme having an amino acid sequence of SXMC (SEQ ID NO: 4) or GXXXXF (SEQ ID NO: 5) for additionally active epimerization activity Were selected (Table 2).
  • the selected amino acid gene is amplified using a polymerase chain reaction (PCR) from gene synthesis or chromosomal DNA (genomic DNA) of each distribution strain, and each amplified DNA is amplified using DNA assembly methods.
  • E. coli expression plasmid vector pET21a (Novagen) was inserted, and a recombinant expression vector was produced.
  • the expression vector is a conventional transformation method [see: Sambrook et al. 1989] E. coli ( E. coli ) BL21 (DE3) strain was transformed into each strain to prepare a transforming microorganism.
  • the Pycose-6-phosphate 3-epimerase of SEQ ID NOs: 6 to 26 was transformed into E. coli BL21 (DE3) strain, respectively.
  • KCCM12494P E.coil BL21 (DE3) / pET-CJ-fep19
  • KCCM12495P E.coil BL21(DE3)/pET-CJ-fep20
  • KCCM12496P E.coil BL21(DE3)/pET-C
  • each of the transformed microorganisms prepared in Example 1 was inoculated into a culture tube containing 5 ml of LB liquid medium, and seed cultured in a shaking incubator at 37°C until the absorbance at 600 nm became 2.0. Was done.
  • the seed culture was inoculated into a culture flask containing an LB liquid medium to carry out the main culture.
  • 1 mM IPTG was added to induce expression and production of the recombinant enzyme.
  • the stirring speed during the cultivation process was 180 rpm and the cultivation temperature was maintained at 37°C.
  • the culture medium was centrifuged at 4° C. for 20 minutes at 8,000 ⁇ g, and the cells were recovered.
  • the recovered cells were washed twice with 50 mM Tris-HCl (pH 8.0) buffer solution, suspended in the same buffer solution, and disrupted the cells using an ultrasonic cell disruptor.
  • the cell lysate was centrifuged at 4° C. for 20 minutes at 13,000 ⁇ g, and then only the supernatant was taken.
  • the recombinant enzyme was purified from the supernatant using His-tag affinity chromatography, dialyzed against 50 mM Tris-HCl (pH 8.0) buffer, and used for the reaction.
  • Example 3 Psychos-6-phosphate 3-epimerization enzyme modeling, Pycose 3-epimerization activity confirmation and sequence comparison
  • amino acid sequence of SEQ ID NO: 9 known as ribulose-phosphate-3-epimerase, was input to I-TASSER, Phyre2, and Galaxyweb server to analyze the protein structure.
  • the enzyme has a TIM-barrel fold in which the ⁇ -sheet is located in the center and the ⁇ -helix structure surrounds it, and the structure expected to be a lycose or lycose-6-phosphate binding site (TIM- barrel fold) inner motifs I (VDG) and III (MXX-X'-PG) were selected (Fig. 1, Blue dotted circle (motif I), Red dotted circle (motif III), example structure-model (SEQ ID NO: 9) )).
  • the inventors of the present invention predict that structurally aspartic acid (D) of (MXXDPG) has a negative charge and affects the 3-epimerization activity of psychos, thereby affecting the 3-epimerization activity of psychos.
  • motif III MXX-X'-PG predicted not to be given, enzymes having an N/K in which X'has a different charge from aspartic acid were selected (WP_085113038, PKM55438, WP_117016900).
  • the psychotic 3-epimerization activity may vary depending on the type of specific motif in the enzyme.
  • the activity of the enzyme ribulose-phosphate-3-epimerase which is an enzyme that converts cycose-6-phosphate of the present application, is 50 mM fructose-6-phosphate or 20 mM glucose-1-phosphate in 50 mM Tris-HCl (pH 7.0) or 50 mM Sodium-posphate (pH 6-7) or 50 mM Potassium-posphate (pH 6-7) after suspension in a buffer solution, phosphoglucomutase or phosphomannomutase and glucose-6-phosphate 0.1 unit/ml of the isomerization enzyme, the thycose-6-phosphate dephosphorylating enzyme, and the recombinant ribulose-phosphate-3-epimerase prepared in Example 2 were added, respectively, at 45° C. to 70° C. for 1 to 24 hours. Reacted.
  • Pycose was added to 50 mM Tris-HCl (pH 7.0) or 50 mM Sodium-posphate (pH 6-7) or 50 mM Potassium-posphate (pH 6-7) buffer. After suspending at a concentration of 1% (w/v), 0.1 unit/ml of ribulose-phosphate-3-epimerase was added, and reacted at 45°C to 70°C for 1 to 24 hours.
  • the generation of glucose, fructose, and thycose was analyzed using HPLC, and the HPLC analysis was performed using an SP_0810 (Shodex) column and an Aminex HPX-87C (Bio-RAD) column at 80°C as a mobile phase at a flow rate of 0.6 ml/min. It was carried out while flowing with a Refractive Index Detector (RID), and it was confirmed by qualitative and quantitative evaluation of glucose, fructose, and psychos, which are common sugars produced by mixing with the above enzymes, respectively. In the quantitative evaluation, the tolerance of the fructose conversion ratio was set to within 5% in consideration of the LC sensitivity, the rapid substrate conversion rate, and the naturally occurring experimental error according to the substrate concentration.
  • RID Refractive Index Detector
  • Table 2 distinguishes among the various ribulose-phosphate-3-epimerization enzymes exhibiting Psychos 6 phosphate 3-epimerization activity, enzymes without Psicose 3-epimerization activity based on the presence or absence of MXXN/KPG and VDG motifs From this, a specific motif, specifically, the motif of SEQ ID NO: 1, does not include the motif of SEQ ID NO: 2, and instead, an enzyme containing the motif of SEQ ID NO: 3 at the same site is specific for Cycos 6-phosphate. It was confirmed that it has a high epimerization activity. In addition, as confirmed in sequences A and B, it was confirmed that when Motif I and III were included, they could have high epimerization activity specifically for Psychos 6-phosphate.
  • Glucan phosphorylase pullulanase, 4-alpha-glucanotransferase, phosphoglucomutase, glucose-6-phosphate isomerase, and thycose-6-phosphate to produce psychoses from maltodextrin.
  • the dephosphorylating enzyme and the fructose-6-phosphate-3-epimerase of the present application were reacted simultaneously (one-pot).
  • each of the seven enzymes was added to a solution in which 5% (w/v) maltodextrin was added to 1-5 mM MgCl 2 , 10-50 mM sodium phosphate pH 7.0. Then, it was reacted at 50° C. for 12 hours.
  • the reaction product was analyzed for the thycose using HPLC.
  • HPLC analysis was performed using an Aminex HPX-87C (Bio-RAD) column at 80° C. while flowing to the mobile phase at a flow rate of 0.6 ml/min, and detected with a Refractive Index Detector. As a result, it was confirmed that psychoses were generated from maltodextrin by a complex enzyme reaction.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PCT/KR2020/005701 2019-05-21 2020-04-29 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소 Ceased WO2020235830A1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202080028788.0A CN114008198B (zh) 2019-05-21 2020-04-29 具有低副反应性的磷酸核酮糖3-差向异构酶基序和包含该基序的酶
AU2020279663A AU2020279663B2 (en) 2019-05-21 2020-04-29 Ribulose-Phosphate 3-Epimerase Motif Having Low Side Reactivity And Enzyme Including The Same
JP2021549965A JP7410162B2 (ja) 2019-05-21 2020-04-29 副反応性が低いリブロースリン酸３－エピメラーゼのモチーフ及びそれを含む酵素
US17/612,970 US12371686B2 (en) 2019-05-21 2020-04-29 Ribulose-phosphate 3-epimerase motif having low side reactivity and enzyme including the same
EP20809298.1A EP3916089A4 (en) 2019-05-21 2020-04-29 RIBULOSE PHOSPHATE-3-EPIMERASE MOTIF WITH LOWER SIDE REACTIVITY AND ENZYME SO
JP2023128141A JP7566993B2 (ja) 2019-05-21 2023-08-04 副反応性が低いリブロースリン酸３－エピメラーゼのモチーフ及びそれを含む酵素

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0059697 2019-05-21
KR1020190059697A KR102080886B1 (ko) 2019-05-21 2019-05-21 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소

Publications (1)

Publication Number Publication Date
WO2020235830A1 true WO2020235830A1 (ko) 2020-11-26

Family

ID=69637216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/005701 Ceased WO2020235830A1 (ko) 2019-05-21 2020-04-29 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소

Country Status (7)

Country Link
US (1) US12371686B2 (https=)
EP (1) EP3916089A4 (https=)
JP (2) JP7410162B2 (https=)
KR (1) KR102080886B1 (https=)
CN (1) CN114008198B (https=)
AU (1) AU2020279663B2 (https=)
WO (1) WO2020235830A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102080886B1 (ko) 2019-05-21 2020-02-24 씨제이제일제당 주식회사 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소
US20220372535A1 (en) * 2019-10-28 2022-11-24 Samyang Corporation Fructose-6-phosphate 3-epimerase and use thereof
US20230183768A1 (en) * 2020-05-18 2023-06-15 Bonumose, Inc. Enzymatic production of allulose
CN120858175A (zh) * 2023-02-28 2025-10-28 嘉吉公司 用于生产d-阿洛酮糖的遗传修饰的微生物和发酵工艺

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084986A2 (en) * 2002-04-04 2003-10-16 Affinium Pharmaceuticals, Inc. Novel purified polypeptides involved in cellular metabolism
WO2004042043A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial ribulose-phosphate 3-epimerases
KR20180004023A (ko) 2016-06-30 2018-01-10 씨제이제일제당 (주) 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법
WO2018112139A1 (en) 2016-12-14 2018-06-21 Bonumose Llc Enzymatic production of d-allulose
WO2018129275A1 (en) 2017-01-06 2018-07-12 Greenlight Biosciences, Inc. Cell-free production of sugars
WO2018132871A1 (en) * 2017-01-17 2018-07-26 Macquarie University Method of producing chemicals in yeast
KR101965509B1 (ko) * 2017-11-15 2019-04-03 씨제이제일제당 (주) 신규한 d-사이코스 3-에피머화 효소 및 이를 이용한 d-사이코스의 제조 방법
KR102080886B1 (ko) * 2019-05-21 2020-02-24 씨제이제일제당 주식회사 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200857D0 (sv) * 2002-03-19 2002-03-19 Forskarpatent I Syd Ab Metabolic engineering for improved xylose utilisation of saccharomyces cerevisiae
US10006033B2 (en) 2013-03-14 2018-06-26 The Regents Of The University Of California Recombinant microorganisms having a methanol elongation cycle (MEC)
KR101473918B1 (ko) * 2014-05-28 2014-12-17 대상 주식회사 사이코스 에피머화 효소, 이의 제조방법 및 이를 이용한 사이코스의 제조방법
EP3663397A4 (en) * 2017-07-31 2021-04-28 CJ Cheiljedang Corporation NEW PSICOSE-6-PHOSPHATE-PHOSPHATASE, COMPOSITION FOR THE MANUFACTURING OF PSICOSE INCLUDING THIS ENZYME, PROCESS FOR MANUFACTURING PSICOSE USING THIS ENZYME

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084986A2 (en) * 2002-04-04 2003-10-16 Affinium Pharmaceuticals, Inc. Novel purified polypeptides involved in cellular metabolism
WO2004042043A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial ribulose-phosphate 3-epimerases
KR20180004023A (ko) 2016-06-30 2018-01-10 씨제이제일제당 (주) 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법
WO2018112139A1 (en) 2016-12-14 2018-06-21 Bonumose Llc Enzymatic production of d-allulose
WO2018129275A1 (en) 2017-01-06 2018-07-12 Greenlight Biosciences, Inc. Cell-free production of sugars
WO2018132871A1 (en) * 2017-01-17 2018-07-26 Macquarie University Method of producing chemicals in yeast
KR101965509B1 (ko) * 2017-11-15 2019-04-03 씨제이제일제당 (주) 신규한 d-사이코스 3-에피머화 효소 및 이를 이용한 d-사이코스의 제조 방법
KR102080886B1 (ko) * 2019-05-21 2020-02-24 씨제이제일제당 주식회사 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Atlas Of Protein Sequence And Structure,", 1979, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 353 - 358
"Guide to Huge Computers", 1994, ACADEMIC PRESS
ATSCHUL, S. F. ET AL., J MOLEC BIOL, vol. 215, no. 403, 1990
CARILLO ET AL., SIAMJAPPLIED MATH, vol. 48, no. 1073, 1988
DATABASE Protein 1 August 2017 (2017-08-01), "ribulose-phosphate 3-epimerase [Thermoflavimicrobium dichotomicum]", XP055762946, retrieved from ncbi Database accession no. WP_093231204.1 *
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. 387, 1984
GRIBSKOV ET AL., NUCL. ACIDS RES., vol. 14, no. 6745, 1986
KWANGSOO KIM ET AL., CRYSTAL STRUCTURE OF D-PSICOSE 3-EPIMERASE FROM AGROBACTERIUM TUMEFACIENS AND ITS COMPLEX WITH TRUE SUBSTRATE D-FRUCTOSE, vol. 361, no. 5, 1 September 2006 (2006-09-01), pages 920 - 931
NEEDLEMAN ET AL., J MOL BIOL., vol. 48, no. 443, 1970
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444
RICE ET AL.: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS GENET, vol. 16, 2000, pages 276 - 277, XP004200114, DOI: 10.1016/S0168-9525(00)02024-2
SMITHWATERMAN, ADV. APPL. MATH, vol. 2, no. 482, 1981

Also Published As

Publication number Publication date
CN114008198A (zh) 2022-02-01
KR102080886B1 (ko) 2020-02-24
US12371686B2 (en) 2025-07-29
US20230051519A1 (en) 2023-02-16
JP2022522693A (ja) 2022-04-20
JP7566993B2 (ja) 2024-10-15
JP7410162B2 (ja) 2024-01-09
AU2020279663B2 (en) 2023-04-13
EP3916089A4 (en) 2022-05-11
AU2020279663A1 (en) 2021-09-30
CN114008198B (zh) 2024-06-07
JP2023166380A (ja) 2023-11-21
EP3916089A1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
WO2020235830A1 (ko) 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소
WO2020122504A1 (ko) 신규 싸이코스-6-인산의 탈인산화 효소, 이를 포함하는 싸이코스 생산용 조성물, 및 이를 이용한 싸이코스 제조방법
WO2018182354A1 (ko) 타가토스 생산용 조성물 및 이를 이용한 타가토스 제조방법
WO2020027362A1 (ko) 신규 아데닐로석시네이트 신세타아제 및 이를 이용한 퓨린 뉴클레오티드 생산방법
WO2019135639A1 (ko) 신규 폴리펩타이드 및 이를 이용한 imp 생산방법
WO2019117671A1 (ko) 5'-이노신산을 생산하는 미생물 및 이를 이용한 5'-이노신산의 생산 방법
WO2019027173A2 (ko) 신규한 싸이코스-6-인산 탈인산효소, 상기 효소를 포함하는 사이코스 생산용 조성물, 상기 효소를 이용하여 사이코스를 제조하는 방법
WO2014193183A1 (ko) 시알산 유도체의 제조방법
WO2021167414A1 (ko) 퓨린 뉴클레오티드를 생산하는 미생물 및 이를 이용한 퓨린 뉴클레오티드의 생산방법
WO2023068472A1 (ko) 신규한 당전이효소 및 이의 용도
WO2022255839A1 (ko) 신규한 yhhs 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법
WO2019004779A2 (ko) 신규한 o-숙시닐 호모세린 트랜스퍼라제 변이체 및 이를 이용한 o-숙시닐 호모세린의 제조방법
WO2015199386A1 (ko) 가용성 단백질 발현량이 증대된 헬리코박터 파일로리 유래 α-1,2 푸코실 전달효소의 유전자와 단백질 및 α-1,2 푸코실올리고당 생산에의 응용
WO2023068722A1 (ko) 리바우디오사이드 d 및 리바우디오사이드 m을 제조하는 방법
WO2016013844A1 (ko) 페닐아세틸 호모세린 락톤 유도체의 생산 방법
WO2020075943A1 (ko) 고활성의 말산 탈수소효소가 도입된 숙신산 생성용 변이 미생물 및 이를 이용한 숙신산 제조방법
WO2020067781A1 (ko) 신규 과당-4-에피머화 효소 및 이를 이용한 타가토스의 제조 방법
WO2023277307A1 (ko) 고농도 l-글루탐산을 생산하기 위한 균주 및 이를 이용한 l-글루탐산 생산방법
WO2019112368A1 (ko) 신규한 사이코스-6-인산 탈인산효소, 상기 효소를 포함하는 사이코스 생산용 조성물, 상기 효소를 이용하여 사이코스를 제조하는 방법
WO2021150019A1 (ko) 타가토스 생산용 조성물 및 이를 이용한 타가토스 제조 방법
WO2019004780A2 (ko) 신규한 o-숙시닐 호모세린 트랜스퍼라제 변이체 및 이를 이용한 o-숙시닐 호모세린의 제조방법
WO2020067786A1 (ko) 신규 과당-4-에피머화 효소 및 이를 이용한 타가토스의 제조 방법
WO2024144270A1 (ko) 알룰로스 3-에피머화 변이 효소 및 이의 용도
WO2019031804A2 (ko) 목적 유전자 발현 조절을 위한 대장균 및 코리네박테리움 글루타미쿰 셔틀 벡터
WO2025143773A1 (ko) 수크로우스 합성효소 변이체, udp-글루코실트랜스퍼라제 변이체 및 이들의 스테비올 배당체 생산 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20809298

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020809298

Country of ref document: EP

Effective date: 20210817

ENP Entry into the national phase

Ref document number: 2021549965

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020279663

Country of ref document: AU

Date of ref document: 20200429

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWG Wipo information: grant in national office

Ref document number: 17612970

Country of ref document: US